Previous studies have reported fewer cases of Coronavirus disease 2019 (COVID-19) in children than in adults, and to date there is limited literature about the clinical course and outcomes in neonates [1, 2]. Not inappropriately the focus of COVID-19 therapies has been in adults, especially the aged. However, it is clear that an immature immune system makes neonates, especially those in the NICU, highly vulnerable to infections generally [3, 4], and thus probably also for COVID-19. One case series has suggested that the younger the child, the higher risk of severe COVID-19 disease [5]. The first report of a neonate with COVID-19 infection was a 17 days old boy who recovered [6]. At the time of writing, complete data 1 on 35 neonates have been included in the database EPICENTRE [7]. Vertical risk was present in 33 neonates, and only two infants were reported to have community exposure. As more neonates are included in well-designed databases, the more we understand the risks, clinical spectrum, severity and complications in this patient population. Moreover, we can focus on ways to prevent COVID-19 infections in neonates born from an infected mother, or neonates that are infected in the community, whether at home, in hospital, by health care workers or families, especially during any potential new pandemic waves.